Version history

{
  "session_id": "sess_SDA-2026-04-10-gap-debate-20260410-112348-a10cb6b4",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "minimax:MiniMax-M2.7",
  "action": "synthesize",
  "content": "\n\n{\n  \"ranked_hypotheses\": [\n    {\n      \"rank\": 1,\n      \"hypothesis_id\": \"H1\",\n      \"title\": \"Impaired TFEB Nuclear Import as Primary Driver, Not Compensatory Failure\",\n      \"composite_score\": 0.52,\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.82,\n        \"evidence_strength\": 0.48,\n        \"novelty\": 0.55,\n        \"feasibility\": 0.62,\n        \"therapeutic_potential\": 0.58,\n        \"druggability\": 0.38,\n        \"safety_profile\": 0.35,\n        \"competitive_landscape\": 0.45,\n        \"data_availability\": 0.58,\n        \"reproducibility\": 0.52\n      },\n      \"evidence_for\": [\n        {\"claim\": \"mTORC1 directly phosphorylates TFEB at S211 to control nucleocytoplasmic shuttling\", \"pmid\": \"20679224\"},\n        {\"claim\": \"mTORC1 hyperactivation in Alzheimer's disease brains correlates with reduced nuclear TFEB\", \"pmid\": \"29727682\"},\n        {\"claim\": \"Pharmacological mTORC1 inhibition restores TFEB nuclear localization and improves clearance in Parkinson's models\", \"pmid\": \"25437564\"},\n        {\"claim\": \"TFEB overexpression is sufficient to reduce α-synuclein and tau aggregation in cell models\", \"pmid\": \"29515023\"},\n        {\"claim\": \"Direct molecular mechanism (S211 phosphorylation creating 14-3-3 binding site) provides clear testable framework\", \"source\": \"Theorist\"},\n        {\"claim\": \"Nuclear TFEB reduction demonstrable before protein aggregates in multiple models\", \"source\": \"Theorist assertion\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Temporal causality is correlative, not demonstrated; end-stage tissue studies cannot establish upstream causation\", \"pmid\": \"29727682\"},\n        {\"claim\": \"mTORC1 hyperactivation is not specific mechanism - mTORC1 regulates hundreds of substrates beyond TFEB\", \"pmid\": \"25437564\"},\n        {\"claim\": \"Temsirolimus Phase II trial in Alzheimer's showed no cognitive benefit\", \"pmid\": \"NCT02049343\"},\n        {\"claim\": \"Everolimus Alzheimer's trial terminated with no signal\", \"pmid\": \"NCT02336633\"},\n        {\"claim\": \"Conditional neuronal TFEB knockout does not cause rapid/spontaneous neurodegeneration\", \"source\": \"Skeptic\"},\n        {\"claim\": \"BBB penetration: Rapamycin has CSF:plasma ratio ~0.05\", \"source\": \"Expert\"},\n        {\"claim\": \"Chronic mTORC1 inhibition causes immunosuppression, contraindicated in elderly patients\", \"source\": \"Expert\"},\n        {\"claim\": \"S211 is not the only regulatory site - S142 and other sites also regulate TFEB localization\", \"pmid\": \"20679224\"}\n      ],\n      \"knowledge_edges\": [\n        {\"from\": \"mTORC1\", \"to\": \"TFEB\", \"relation\": \"phosphorylates_at_S211\", \"direction\": \"inhibits_nuclear_import\"},\n        {\"from\": \"14-3-3\", \"to\": \"TFEB\", \"relation\": \"binds_phosphorylated_S211\", \"direction\": \"cytoplasmic_sequestration\"},\n        {\"from\": \"TFEB\", \"to\": \"CLEAR_network\", \"relation\": \"transcriptionally_regulates\", \"direction\": \"upregulates_autophagy\"},\n        {\"from\": \"TFEB\", \"to\": \"α-synuclein/tau\", \"relation\": \"clearance_target\", \"direction\": \"reduces_aggregation\"},\n        {\"from\": \"mTORC1\", \"to\": \"S6K/4E-BP1\", \"relation\": \"phosphorylates\", \"direction\": \"parallel_pathways\"},\n        {\"from\": \"mTORC1_inhibitors\", \"to\": \"synaptic_plasticity\", \"relation\": \"adverse_effect\", \"direction\": \"impairs_memory\"}\n      ],\n      \"expert_notes\": \"Despite clinical failures, the mechanistic foundation remains compelling. Translation failure may reflect timing (late-stage intervention), BBB penetration, or pathway specificity rather than mechanism invalidity.\"\n    },\n    {\n      \"rank\": 2,\n      \"hypothesis_id\": \"H2\",\n      \"title\": \"Biphasic TFEB Response—Compensatory Then Destructive\",\n      \"composite_score\": 0.48,\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.68,\n        \"evidence_strength\": 0.52,\n        \"novelty\": 0.62,\n        \"feasibility\": 0.55,\n        \"therapeutic_potential\": 0.72,\n        \"druggability\": 0.32,\n        \"safety_profile\": 0.42,\n        \"competitive_landscape\": 0.40,\n        \"data_availability\": 0.45,\n        \"reproducibility\": 0.50\n      },\n      \"evidence_for\": [\n        {\"claim\": \"TFEB expression increases in early Alzheimer's and Parkinson's disease brains\", \"pmid\": \"30545709\"},\n        {\"claim\": \"Acute TFEB activation is neuroprotective in multiple models\", \"pmid\": \"29727682\"},\n        {\"claim\": \"Chronic activation shows diminishing returns over time\", \"pmid\": \"29727682\"},\n        {\"claim\": \"Negative feedback: mTORC1 reactivation and 14-3-3 overexpression follow prolonged TFEB activation\", \"pmid\": \"25437564\"},\n        {\"claim\": \"TFEB target genes become progressively silenced in aged neurons despite continued TFEB protein expression\", \"source\": \"Aging Methylome Atlas\"},\n        {\"claim\": \"Explains therapeutic window prediction - beneficial early, limited late-stage benefit\", \"source\": \"Theorist\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Epigenetic silencing mechanisms (HDAC3, EZH2) predicted but not validated in neurodegeneration models\", \"source\": \"Theorist\"},\n        {\"claim\": \"No biomarkers currently exist to identify which phase a patient is in\", \"source\": \"Expert\"},\n        {\"claim\": \"Drugging the therapeutic window requires precise",
  "tokens_used": "1292",
  "persona_id": "persona-synthesizer"
}